/APTA.ST

APTA.ST Stock - Aptahem AB (publ)

Q: What is the analyst price target for APTA.ST?

Analyst price target information is not currently available for APTA.ST.

Q: What is APTA.ST's market cap?

Market capitalization information is not currently available for APTA.ST.

Healthcare|Biotechnology|STO

$1.12+34.29%

+$0.29 (+34.29%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1.23

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for APTA.ST

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.46

52W High$2.40

52W Low$0.56

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$3.77M	$2.63M	$3.45M	N/A	N/A
Gross Profit	$3.77M	$2.63M	$-71,780	$-61,763	$-73,806
Gross Margin	100.0%	100.0%	-2.1%	N/A	N/A
Operating Income	$-8,184,339	$-10,104,760	$-9,137,890	$-28,544,640	$-24,275,640
Net Income	$-8,568,467	$-11,112,869	$-8,864,906	$-28,474,724	$-24,275,778
Net Margin	-227.2%	-422.4%	-257.1%	N/A	N/A
EPS	$-0.69	$-4.66	$-4.21	$-18.88	$-28.10

Company Overview

Aptahem AB (publ), a clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in preclinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children's Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.

Visit Website